Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix.

Boerrigter PJ, de Bie JJ, Mannaerts BM, van Leeuwen BP, Passier-Timmermans DP

Human reproduction (Oxford, England)1 Aug 2002Cited by 23 (Europe PMC)

PMID12151432DOI10.1093/humrep/17.8.2027PepBankPUB-12151432

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studySafety outcome
After IVF stimulation, ganirelix exposure was not linked to different pregnancy loss after 16 weeks versus GnRH agonist treatment.
In plain wordsAfter IVF stimulation, pregnancy loss after 16 weeks did not differ between ganirelix and GnRH agonist groups.
Peptide
Ganirelix
Outcome
No significant changePregnancy loss after 16 weeks
Study
n: not reported in source
Comparator
GnRH agonist long protocol
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
There were no differences between the two groups in pregnancy loss after 16 weeks gestation.
2 context sentences(design, population, supporting numbers)
Summary · context
To establish long-term safety, follow-up data on pregnancy, birth and neonatal outcome were collected during clinical development trials with ganirelix (Orgalutran) in women undergoing controlled ovarian stimulation for conventional IVF or ICSI.
Summary · context
Obstetrical data on 340 ongoing pregnancies ( vertical line16 gestational weeks) after ganirelix treatment and 134 pregnancies after GnRH agonist treatment in a long protocol are shown.
Report a problemFND-1215143201
02HumanObservational studySafety outcome
After IVF stimulation, complication incidence and nature during pregnancy and delivery did not differ between ganirelix and GnRH agonist groups.
In plain wordsAfter IVF stimulation, pregnancy and delivery complications did not differ between ganirelix and GnRH agonist groups.
Peptide
Ganirelix
Outcome
No significant changePregnancy and delivery complications
Study
n: not reported in source
Comparator
GnRH agonist long protocol
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Incidence and nature of complications during pregnancy and delivery did not differ between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
To establish long-term safety, follow-up data on pregnancy, birth and neonatal outcome were collected during clinical development trials with ganirelix (Orgalutran) in women undergoing controlled ovarian stimulation for conventional IVF or ICSI.
Summary · context
Obstetrical data on 340 ongoing pregnancies ( vertical line16 gestational weeks) after ganirelix treatment and 134 pregnancies after GnRH agonist treatment in a long protocol are shown.
Report a problemFND-1215143202
03HumanObservational studySafety outcome
After IVF stimulation, neonatal characteristics showed no major differences between ganirelix and agonist groups, with reported overall birth weights by plurality.
In plain wordsAfter IVF stimulation, neonatal characteristics showed no major differences between ganirelix and GnRH agonist groups.
Peptide
Ganirelix
Outcome
No significant changeNeonatal characteristics and birth weight
Study
n: not reported in source
Comparator
GnRH agonist long protocol
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Overall mean singleton birth weight
3200 g
both groups
Overall mean twin birth weight
2300 g
both groups
Overall mean triplet birth weight
1800 to 1900 g
both groups
Source sentences
Summary
No major differences were observed in neonatal characteristics of infants in the ganirelix and agonist groups, who had an overall mean birth weight of on average 3200 g for singletons, 2300 g for twins and 1800-1900 g for triplets.
2 context sentences(design, population, supporting numbers)
Summary · context
To establish long-term safety, follow-up data on pregnancy, birth and neonatal outcome were collected during clinical development trials with ganirelix (Orgalutran) in women undergoing controlled ovarian stimulation for conventional IVF or ICSI.
Summary · context
Obstetrical data on 340 ongoing pregnancies ( vertical line16 gestational weeks) after ganirelix treatment and 134 pregnancies after GnRH agonist treatment in a long protocol are shown.
Report a problemFND-1215143203
04HumanObservational studySafety outcome
After IVF stimulation, congenital malformations occurred in 32 of 424 fetuses after ganirelix versus 10 of 181 after agonist treatment.
In plain wordsAfter IVF stimulation, malformations occurred in 7.5% of assessed ganirelix-exposed fetuses versus 5.5% after GnRH agonists.
Peptide
Ganirelix
Outcome
IncreaseCongenital malformations
Study
n: not reported in source
Comparator
GnRH agonist long protocol
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Malformations
7.5%
ganirelix
Malformations
5.5%
agonist
Fetuses with congenital malformations
32 fetuses
ganirelix group, of 424 fetuses
Fetuses with congenital malformations
10 fetuses
agonist group, of 181 fetuses
Source sentences
Summary
Congenital malformations were observed in 32 of 424 (7.5%) fetuses vertical line26 gestational weeks in the ganirelix group and in 10 of 181 (5.5%) in the agonist group.
2 context sentences(design, population, supporting numbers)
Summary · context
To establish long-term safety, follow-up data on pregnancy, birth and neonatal outcome were collected during clinical development trials with ganirelix (Orgalutran) in women undergoing controlled ovarian stimulation for conventional IVF or ICSI.
Summary · context
Obstetrical data on 340 ongoing pregnancies ( vertical line16 gestational weeks) after ganirelix treatment and 134 pregnancies after GnRH agonist treatment in a long protocol are shown.
Report a problemFND-1215143204
05HumanObservational studySafety outcome
After IVF stimulation, broadly defined major malformation rates were 4.5 versus 3.3 for ganirelix and agonists, with odds ratio 1.37 (95% CI 0.54-3.48).
In plain wordsAfter IVF stimulation, broadly defined major malformation rates were 4.5 after ganirelix versus 3.3 after GnRH agonists.
Peptide
Ganirelix
Outcome
IncreaseMajor congenital malformations
Study
n: not reported in source
Comparator
GnRH agonist long protocol
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Major malformation rate, broad definition
4.5
ganirelix group
Major malformation rate, broad definition
3.3
agonist group
Odds ratio
1.37 ratio
ganirelix versus agonist
95% confidence interval of odds ratio
0.54 to 3.48 ratio
ganirelix versus agonist
Source sentences
Summary
When applying a broad definition of major malformation (a major congenital malformation is a condition that causes functional impairment or requires surgical intervention) the rates were 4.5 versus 3.3 (odds ratio 1.37, 95% confidence interval 0.54-3.48) for the ganirelix and agonist group respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
To establish long-term safety, follow-up data on pregnancy, birth and neonatal outcome were collected during clinical development trials with ganirelix (Orgalutran) in women undergoing controlled ovarian stimulation for conventional IVF or ICSI.
Summary · context
Obstetrical data on 340 ongoing pregnancies ( vertical line16 gestational weeks) after ganirelix treatment and 134 pregnancies after GnRH agonist treatment in a long protocol are shown.
Report a problemFND-1215143205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.